Pacific Biosciences Has 'Long Road' Ahead, But Cantor Still Bullish By: Benzinga via Benzinga October 01, 2015 at 14:23 PM EDT Cantor Fitzgerald reiterated a Buy rating and $9.00 price target on shares of Pacific Biosciences of California (NASDAQ: PACB) on ... Read More >> Related Stocks: Illumina Inc Pacific Biosciences Roche Holding AG Basel American Depositary Shares